基于慢性阻塞性肺疾病急性加重期患者采取阿奇霉素联合头孢类药物治疗的药学研究

Pharmaceutical Study of Azithromycin+Cephalosporins in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的探讨阿奇霉素联合头孢类药物在慢性阻塞性肺疾病急性加重期治疗中的应用效果及药学分析。方法根据先后入院时间平均划分2018年1月至2018年12月本院接收的82例慢性阻塞性肺疾病急性加重期患者,每组41例,对照组开展单一的头孢类药物治疗,研究组则接受阿奇霉素联合头孢类药物治疗,统计各组治疗效果。结果在治疗总有效率方面,研究组是92.68%,对照组是75.61%,研究组较对照组更高,差异有统计学意义(P<0.05);在PEF及FEV1/FVC方面,治疗后,研究组均优于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论慢性阻塞性肺疾病急性加重期治疗过程中,阿奇霉素联合头孢类药物应用效果明显,不仅可以减轻患者临床病症,同时有助于肺功能改善。

Objective To investigate the effect of Azithromycin combined with cephalosporins in the treatment of acute exacerbation of chronic obstructive pulmonary disease(COPD) and its pharmaceutical analysis. Methods According to the average time of admission, 82 patients with acute exacerbation of chronic obstructive pulmonary disease received in our hospital from January 2018 to December 2018 were divided into 41 cases in each group. The control group received a single cephalosporin treatment, while the research group received Azithromycin combined with cephalosporin treatment. The therapeutic effect of each group was analyzed. Results The total effective rate of the study group was 92.68% and that of the control group was 75.61%. The study group was higher than that of the control group(P<0.05). In PEF and FEV1/FVC, the study group was better than that of the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Azithromycin combined with cephalosporins is effective in the treatment of acute exacerbation of chronic obstructive pulmonary disease, which can not only alleviate the clinical symptoms of patients, but also help to improve pulmonary function.